cat no | io1076
ioGlutamatergic Neurons PINK1 Q456X/Q456X are opti‑ox deterministically programmed glutamatergic neurons carrying a genetically engineered homozygous Q456X mutation in the PINK1 gene encoding the protein PTEN induced putative kinase 1. These cells offer a rapidly maturing, disease relevant system for investigating the role of PINK1 Q456X mutation in early-onset Parkinson's disease (PD).
This disease model is part of a Parkinson's disease panel of physiologically relevant human iPSC-derived cells that can be incorporated into translational research and drug discovery workflows. An additional clone for the PINK1 Q456X hom mutation is available for scientists who wish to repeat their experiments in multiple independent clones, please enquire. Additional mutations in the PD panel include a heterozygous PINK1 Q456X mutation, PRKN R275W, SNCA A53T and GBA mutations. All can be used alongside their genetically matched control, ioGlutamatergic Neurons.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Make True Comparisons
Pair the Parkinson's disease model cells with the genetically matched wild-type ioGlutamatergic Neurons to investigate the impact of the PINK1 nonsense mutation on early-onset PD.
Scalable
With opti-ox technology, we can make billions of consistently deterministically programmed cells, surpassing the demands of industrial workflows.
Quick
The disease model cells and wild-type control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
ioGlutamatergic Neurons PINK1 Q456X/Q456X express neuron-specific markers comparably to the wild-type control
ioGlutamatergic Neurons PINK1 Q456X/Q456X form structural neuronal networks by day 11
ioGlutamatergic Neurons PINK1 Q456X/Q456X demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming
Disease-related PINK1 is expressed in ioGlutamatergic Neurons PINK1 Q456X/Q456X following deterministic programming
bit.bio
V11
bit.bio
2024
Professor Deepak Srivastava
Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders
King’s College London
Emmanouil Metzakopian | Vice President, Research and Development | bit.bio
Javier Conde-Vancells | Director Product Management | bit.bio
Chakraborty et al
Nature Communications
2023
Featuring ioGlutamatergic Neurons
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Oosterveen, et al
bit.bio & Charles River Laboratories
2023
Qiaojin Lin et al
The EMBO Journal
2023
Featuring opti-ox powered hiPSC-derived glutamatergic neurons with constitutive expression of Cas9
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
Further your disease research by pairing our wild type cells with isogenic disease models.